CA2065404A1 - Assays and reagents for amyloid deposition - Google Patents

Assays and reagents for amyloid deposition

Info

Publication number
CA2065404A1
CA2065404A1 CA002065404A CA2065404A CA2065404A1 CA 2065404 A1 CA2065404 A1 CA 2065404A1 CA 002065404 A CA002065404 A CA 002065404A CA 2065404 A CA2065404 A CA 2065404A CA 2065404 A1 CA2065404 A1 CA 2065404A1
Authority
CA
Canada
Prior art keywords
amyloid deposition
reagents
assays
alzheimer
dis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002065404A
Other languages
French (fr)
Other versions
CA2065404C (en
Inventor
Barbara Cordell
David Wolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scios LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2065404A1 publication Critical patent/CA2065404A1/en
Application granted granted Critical
Publication of CA2065404C publication Critical patent/CA2065404C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides an in vitro tissue culture-based assay for amyloid deposition specific for Alzheimer's dis-ease which is suitable for routine drug screening analysis. Immunological diagnostic reagents for Alzheimer's disease are also provided.
CA002065404A 1989-09-18 1990-09-12 Assays and reagents for amyloid deposition Expired - Lifetime CA2065404C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40876789A 1989-09-18 1989-09-18
US408,767 1989-09-18
PCT/US1990/005155 WO1991004339A1 (en) 1989-09-18 1990-09-12 Assays and reagents for amyloid deposition

Publications (2)

Publication Number Publication Date
CA2065404A1 true CA2065404A1 (en) 1991-03-19
CA2065404C CA2065404C (en) 2002-12-24

Family

ID=23617679

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002065404A Expired - Lifetime CA2065404C (en) 1989-09-18 1990-09-12 Assays and reagents for amyloid deposition

Country Status (5)

Country Link
EP (1) EP0493470A4 (en)
JP (1) JPH05502368A (en)
AU (1) AU641434B2 (en)
CA (1) CA2065404C (en)
WO (1) WO1991004339A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3249793A (en) 1991-12-24 1993-07-28 Isis Pharmaceuticals, Inc. Compositions and methods for modulating beta -amyloid
US6610493B1 (en) * 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US5872101A (en) * 1995-01-06 1999-02-16 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US7799535B1 (en) * 1997-12-09 2010-09-21 Arch Development Corporation Methods for identifying factors that control the folding of amyloid proteins of diverse origin
EP1793001B1 (en) * 2001-02-15 2011-11-09 The University of Chicago Yeast screens for agents affecting protein folding
US7045290B2 (en) 2001-02-15 2006-05-16 The University Of Chicago Yeast screens for treatment of human disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2403557A1 (en) * 1977-09-19 1979-04-13 Beljanski Mirko METHOD AND REAGENTS FOR DETECTION OF CARCINOGENIC SUBSTANCES AND ANTI-CANCER SUBSTANCES
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US4919915A (en) * 1987-03-03 1990-04-24 Paul Averback Method for detecting the ability to prevent red-to-green congophilic birefringence
ATE169673T1 (en) * 1986-11-17 1998-08-15 Scios Inc RECOMBINED ALZHEIMER AMYLOID PROTEIN
US4912206A (en) * 1987-02-26 1990-03-27 The United States Of America As Represented By The Department Of Health And Human Services CDNA clone encoding brain amyloid of alzheimer's disease
CA1340802C (en) * 1987-08-15 1999-10-26 Yasuyuki Takahashi Senile amyloid precursor protein and an antibody specific for the same
CA1339014C (en) * 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
WO1989006693A1 (en) * 1988-01-13 1989-07-27 The Mclean Hospital Corporation Genetic sequences coding for alzheimer amyloid from brain
AU3204689A (en) * 1988-02-10 1989-09-06 Children's Medical Center Corporation Amyloid protein precursors, genetic probes, antibodies, and methods of use

Also Published As

Publication number Publication date
JPH05502368A (en) 1993-04-28
EP0493470A4 (en) 1992-11-25
CA2065404C (en) 2002-12-24
AU6431190A (en) 1991-04-18
AU641434B2 (en) 1993-09-23
EP0493470A1 (en) 1992-07-08
WO1991004339A1 (en) 1991-04-04

Similar Documents

Publication Publication Date Title
CA2222974A1 (en) Magnetic resonance imaging agents for the detection of physiological agents
AU613881B2 (en) Automated patient sample analysis instrument
ES2070658A1 (en) Diagnostic kit for diagnosing and distinguishing chest pain in early onset thereof
AU8054291A (en) Analytical test devices for competition assay for drugs of non-protein antigens using immunochromatographic techniques
AU672379B2 (en) Diagnostic assay for Alzheimer's Disease based on the proteolysis of Alzheimer's precursor protein
AU5292290A (en) Diagnostic method for alzheimer's disease: examination of non-neural tissue
IT1270130B (en) AUTOMATED DIAGNOSTIC INSTRUMENT IN PARTICULAR FOR THE ANALYSIS OF SAMPLES IN TEST PACKAGES FOR AN ANALYT
AU592041B2 (en) Rapid hybridization assay using latex-immobilized probe
WO1989003846A3 (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
AU8185494A (en) Diagnostic assay for alzheimer's disease
AU1441988A (en) Amyloidosis and alzheimer's disease diagnostic assay and reagents therefor
CA2065404A1 (en) Assays and reagents for amyloid deposition
AU2667197A (en) Stabilized preparations of human troponins and modifications thereof, diagnostic assay methods and assay kits
WO2001016184A3 (en) Diagnostic assay for type 2 heparin-induced thrombocytopenia
AU6709496A (en) Reagent for examining agglutination of virus and kit for virus examination
CA2132708A1 (en) Fluorescence immunoassays using fluorescent dyes free of aggregation and serum binding
WO1998023750A3 (en) Mammalian chemokines
AU6099390A (en) Drug screening assay
AU8944291A (en) Immunoassay for the determination of anti-hiv antibodies in human samples
CA2152166A1 (en) Process for detecting fibrocystic desease or a cftr gene mutation
AU6612290A (en) Differential diagnostic assay for brucellosis
AU1397495A (en) Diagnostic tests and reagents for detecting risk of alzheimer's disease and stroke
USD320280S (en) Sample test card for a biological analyzer
WO1999001085A3 (en) Autoimmune inner ear disease antigen and diagnostic assay
AU1629688A (en) Assay method for the diagnostic of chlamydia infection

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry